File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: An epidemiological association between the trends of nucleoside analogue prescription and liver cancer incidence from 1999 to 2012 in Hong Kong, China

TitleAn epidemiological association between the trends of nucleoside analogue prescription and liver cancer incidence from 1999 to 2012 in Hong Kong, China
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2015
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 50th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress™ 2015), Vienna, Austria, 22-26 April 2015. In Journal of Hepatology, 2015, v. 62 suppl. 2, p. S435, abstract no. P0333 How to Cite?
AbstractBACKGROUND AND AIMS: More than 85% of hepatocellular carcinoma (HCC) in Hong Kong, China is associated with chronic hepatitis B (CHB) infection. Nucleoside analogue therapy for CHB was introduced to Hong Kong since 1999.We determined whether there was a positive effect on the population incidence of liver cancer by the introduction of nucleoside analogue therapy up to 2012. METHODS: We obtained nucleoside analogue (lamivudine, adefovir, telbivudine, entecavir and tenofovir) prescription data (1999–2012) from the electronic health record system of the Hospital Authority, Hong Kong, which provides >90% of secondary and tertiary care to the Hong Kong population. We excluded prescriptions with concomitant anti-HIV medications. Liver cancer data from 1990 to 2012 was obtained from the population-based Hong Kong Cancer Registry. Using Poisson piecewise regression analysis, we compared rate trends of liver cancer incidence from the period of 1990 to 1998 with the period of 1999 to 2012. RESULTS: Nucleoside analogue prescription patient headcount increased from 329 prescriptions in 1999 to 5,942 prescriptions in 2006, then to 26,411 prescriptions in 2012. The increase rate of 1999–2006 and 2006–2012 were 802 and 3,411 prescriptions per year respectively (p < 0.001). Age-standardized incidence of liver cancer, using World Health Organization standard population 2000 as reference, dropped from 22.4 per 100,000 persons in 1998 to 15.4 per 100,000 persons in 2012. After adjusting for the change in local CHB prevalence over the study period, there was a decline in the age-adjusted liver cancer incidence for all patients (2.7%, p < 0.001, 95% CI 1.4–4.0%), male patients (3.5%, p = 0.009, 95% CI 1.1–5.9%) and female patients (2.0%, p < 0.001, 95% CI 1.1–2.9%). When analyzing specific age groups, the decline in liver cancer incidence was most significant among patients aged 50–59 years (male: 15.8%, p = 0.006, 95% CI 5.7–25.9%, female: 7.1%, p = 0.001, 95% 3.4–10.9%), and patients aged 30–39 years (male: 3.8%, p = 0.008, 95% CI 1.3–6.4%; female: 1.3%, p = 0.004, 95% CI 1.1–2.1%). CONCLUSIONS: From this interim analysis, we demonstrated an ecological association of nucleoside analogue prescription with the incidence of liver cancer in a CHB-prevalent region, providing epidemiological evidence that nucleoside analogue therapy for CHB could reduce the risk of HCC. Further analysis will be performed for liver cancer mortality and for more a detailed comparison of different time periods.
DescriptionPoster Presentation: no. P0333
This journal suppl. entitled: Abstracts of The International Liver Congress™ 2015 - 50 Annual meeting of the European Association for the Study of the Liver
Persistent Identifierhttp://hdl.handle.net/10722/216057
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSeto, WK-
dc.contributor.authorLau, EHY-
dc.contributor.authorWu, JT-
dc.contributor.authorHung, IFN-
dc.contributor.authorLeung, WK-
dc.contributor.authorFung, J-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, MF-
dc.date.accessioned2015-08-21T13:51:28Z-
dc.date.available2015-08-21T13:51:28Z-
dc.date.issued2015-
dc.identifier.citationThe 50th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress™ 2015), Vienna, Austria, 22-26 April 2015. In Journal of Hepatology, 2015, v. 62 suppl. 2, p. S435, abstract no. P0333-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/216057-
dc.descriptionPoster Presentation: no. P0333-
dc.descriptionThis journal suppl. entitled: Abstracts of The International Liver Congress™ 2015 - 50 Annual meeting of the European Association for the Study of the Liver-
dc.description.abstractBACKGROUND AND AIMS: More than 85% of hepatocellular carcinoma (HCC) in Hong Kong, China is associated with chronic hepatitis B (CHB) infection. Nucleoside analogue therapy for CHB was introduced to Hong Kong since 1999.We determined whether there was a positive effect on the population incidence of liver cancer by the introduction of nucleoside analogue therapy up to 2012. METHODS: We obtained nucleoside analogue (lamivudine, adefovir, telbivudine, entecavir and tenofovir) prescription data (1999–2012) from the electronic health record system of the Hospital Authority, Hong Kong, which provides >90% of secondary and tertiary care to the Hong Kong population. We excluded prescriptions with concomitant anti-HIV medications. Liver cancer data from 1990 to 2012 was obtained from the population-based Hong Kong Cancer Registry. Using Poisson piecewise regression analysis, we compared rate trends of liver cancer incidence from the period of 1990 to 1998 with the period of 1999 to 2012. RESULTS: Nucleoside analogue prescription patient headcount increased from 329 prescriptions in 1999 to 5,942 prescriptions in 2006, then to 26,411 prescriptions in 2012. The increase rate of 1999–2006 and 2006–2012 were 802 and 3,411 prescriptions per year respectively (p < 0.001). Age-standardized incidence of liver cancer, using World Health Organization standard population 2000 as reference, dropped from 22.4 per 100,000 persons in 1998 to 15.4 per 100,000 persons in 2012. After adjusting for the change in local CHB prevalence over the study period, there was a decline in the age-adjusted liver cancer incidence for all patients (2.7%, p < 0.001, 95% CI 1.4–4.0%), male patients (3.5%, p = 0.009, 95% CI 1.1–5.9%) and female patients (2.0%, p < 0.001, 95% CI 1.1–2.9%). When analyzing specific age groups, the decline in liver cancer incidence was most significant among patients aged 50–59 years (male: 15.8%, p = 0.006, 95% CI 5.7–25.9%, female: 7.1%, p = 0.001, 95% 3.4–10.9%), and patients aged 30–39 years (male: 3.8%, p = 0.008, 95% CI 1.3–6.4%; female: 1.3%, p = 0.004, 95% CI 1.1–2.1%). CONCLUSIONS: From this interim analysis, we demonstrated an ecological association of nucleoside analogue prescription with the incidence of liver cancer in a CHB-prevalent region, providing epidemiological evidence that nucleoside analogue therapy for CHB could reduce the risk of HCC. Further analysis will be performed for liver cancer mortality and for more a detailed comparison of different time periods.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleAn epidemiological association between the trends of nucleoside analogue prescription and liver cancer incidence from 1999 to 2012 in Hong Kong, China-
dc.typeConference_Paper-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailLau, EHY: ehylau@hku.hk-
dc.identifier.emailWu, JT: joewu@hku.hk-
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.emailFung, J: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityLau, EHY=rp01349-
dc.identifier.authorityWu, JT=rp00517-
dc.identifier.authorityHung, IFN=rp00508-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.authorityFung, J=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0168-8278(15)30548-1-
dc.identifier.hkuros248018-
dc.identifier.volume62-
dc.identifier.issuesuppl. 2-
dc.identifier.spageS435, abstract no. P0333-
dc.identifier.epageS435, abstract no. P0333-
dc.identifier.isiWOS:000362830600055-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats